SNDL
SNDL's revenue rose 2.8% to C$946 million in fiscal 2025. Its operating margin was −0.7%, up from −11.3% a year earlier. Free cash flow was C$58 million, up 25.5%. It paid out C$15 million in dividends and buybacks, 26% of free cash flow. The diluted share count fell 2.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
Income statement
SNDL lost money in fiscal 2025: a net loss of C$16 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 561 | 286 | 198 | 246 | 253 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −3,359.4x | −1,953.8x | −2,014.5x | −14.5x | −0.9x |
| Current ratio | 11.1x | 5.6x | 3.9x | 5.1x | 4.9x |
| Quick ratio | 10.6x | 4.2x | 2.7x | 3.7x | 3.5x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 24.9% | 6.3% | 9.0% |
| Altman Z'' | 3.11 | 3.60 | 3.47 |
| Accruals ratio | −10.3% | −10.6% | −6.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put SNDL side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| SNDL | FY25 | 2.8% | −0.7% | 6.1% | — | — | — | |
| USANA Health Sciences | FY25 | 8.3% | 4.0% | 0.9% | — | — | — | Compare |
| Oddity Tech | FY25 | 25.2% | 14.7% | 10.3% | — | −1.5x | — | Compare |
| Trulieve Cannabis | FY25 | −0.5% | 12.2% | 19.4% | 5.8% | −0.2x | 5 | Compare |
| Nu Skin | FY25 | −14.3% | 4.4% | 3.1% | 6.5% | −0.1x | 7 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | 64 | 61 | 56 | 712 | 909 | 920 | 946 |
| Revenue growth | — | — | −4.2% | −7.9% | 1,168.9% | 27.6% | 1.3% | 2.8% |
| Gross profit | — | 36 | −50 | −9 | 140 | 190 | 240 | 259 |
| Research and development | 0 | 2 | 0 | 2 | 2 | 0 | 0 | 0 |
| Operating income | −13 | −52 | −185 | −134 | −348 | −163 | −104 | −6 |
| Net income | −13 | −272 | −233 | −227 | −335 | −173 | −95 | −16 |
| Diluted EPS (CAD) | −2.30 | −31.70 | −1.10 | — | −1.46 | −0.67 | −0.36 | −0.06 |
| Diluted shares (millions) | 6 | 9 | 0 | 0 | 230 | 259 | 264 | 258 |
| Cash flow | ||||||||
| Cash from operations | −5 | −113 | −58 | −156 | −7 | −17 | 55 | 71 |
| Capital expenditure | 8 | 110 | 3 | 4 | 11 | 8 | 9 | 13 |
| Free cash flow | −13 | −223 | −61 | −160 | −17 | −24 | 46 | 58 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 13 | 2 | 13 | 15 |
| Acquisitions | 0 | 77 | 0 | 83 | 29 | 4 | 40 | 3 |
| Stock-based compensation | 5 | 39 | 9 | 12 | 10 | 15 | 20 | 14 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 8 | 45 | 60 | 561 | 286 | 198 | 246 | 253 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — |
| Total assets | — | 510 | 295 | 1,428 | 1,559 | 1,473 | 1,349 | 1,336 |
| Total liabilities | — | 289 | 25 | 98 | 232 | 244 | 216 | 235 |
| Shareholders' equity | 14 | 216 | 272 | 1,329 | 1,306 | 1,212 | 1,133 | 1,101 |
| Margins and ratios | ||||||||
| Gross margin | — | 57.4% | −81.9% | −16.0% | 19.7% | 20.9% | 26.1% | 27.3% |
| Operating margin | — | −82.4% | −304.4% | −239.4% | −48.8% | −17.9% | −11.3% | −0.7% |
| Net margin | — | −427.1% | −382.9% | −404.4% | −47.0% | −19.0% | −10.3% | −1.7% |
| Free cash flow margin | — | −350.9% | −99.3% | −284.2% | −2.4% | −2.7% | 5.0% | 6.1% |
| Rule of 40 (growth + FCF margin) | — | — | −103.5% | −292.1% | 1,166.4% | 24.9% | 6.3% | 9.0% |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −95.6% | −28.4% | −25.4% | −13.7% | −8.1% | −1.4% |
| Return on assets | — | — | −58.0% | −26.4% | −22.4% | −11.4% | −6.7% | −1.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |